University Of Pittsburgh

Medicus Pharma and HelixNano have signed a non-binding memorandum of understanding to develop thermostable mRNA vaccines that eliminate cold-chain storage requirements.

Researchers at the 2025 ASCO Annual Meeting revealed how the tumor microenvironment's complex balance of pro-tumor and anti-tumor immune forces can be manipulated to improve immunotherapy responses.

ECM Therapeutics has received FDA Investigational Device Exemption approval for ECMT-100, a regenerative hydrogel derived from extracellular matrix designed to treat anorectal fistulas non-surgically.

University of Pittsburgh researchers have developed silk iron microparticles (SIMPs) that can be magnetically guided through the body to deliver treatments directly to disease sites like tumors or aneurysms.

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

AbbVie's final analysis of the phase III MIRASOL trial confirms Elahere (mirvetuximab soravtansine) provides superior efficacy compared to chemotherapy in folate receptor alpha-positive platinum-resistant ovarian cancer patients.

A groundbreaking pilot study demonstrates that spinal cord implants delivering low-level electrical stimulation helped three adults with spinal muscular atrophy regain muscle function and mobility.

A novel nasal swab shows promise in differentiating between T2-high and T2-low asthma, offering a more precise diagnosis compared to current methods.

Researchers have identified a novel compound, SYM2081, that targets mast cells to reduce inflammation in skin conditions like rosacea.

Gate Neurosciences and the University of Pittsburgh have started a Phase II trial to assess apimostinel's ability to prolong antidepressant effects when combined with a digital therapeutic.